CCR8抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Huamn lymphoma tissue, Primary antibody: P03804(CCR8 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P03804(CCR8 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P03804(CCR8 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

CCR8. a G protein-coupled chemokine receptor, primarily binds ligands like CCL1 and CCL18. regulating immune cell migration and function. It has gained attention in oncology due to its overexpression on tumor-infiltrating regulatory T cells (Tregs), which suppress anti-tumor immunity. Tumor-associated Tregs exhibit higher CCR8 levels compared to peripheral Tregs, making CCR8 a promising target for selective depletion of immunosuppressive cells within the tumor microenvironment (TME).

CCR8-targeting antibodies are being explored to disrupt the CCR8-CCL1 axis or eliminate CCR8+ Tregs via antibody-dependent cellular cytotoxicity (ADCC). Preclinical studies show that blocking CCR8 reduces Treg infiltration and enhances anti-tumor responses, particularly when combined with checkpoint inhibitors (e.g., anti-PD-1). Early-phase clinical trials are evaluating CCR8 antibodies in solid tumors, leveraging their potential for TME-specific action to minimize systemic toxicity.

Challenges include optimizing selectivity to avoid off-target effects, as CCR8 is expressed on some Th2 cells and endothelial cells. Additionally, CCR8's role as a biomarker for Treg activity is under investigation to stratify patients likely to respond. Emerging strategies include bispecific antibodies and antibody-drug conjugates (ADCs) to enhance efficacy. While still in exploratory stages, CCR8-targeted therapies represent a novel approach to reprogram immunosuppressive TMEs, potentially expanding immunotherapy options for resistant cancers.